Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582061 · ClinicalTrials.gov registry record · Phase 3
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
NCT01582061 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 104 participants.
The verdict
NCT01582061, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
Study Summary
This study provided access to pasireotide sc in patients with Cushing's disease.and provided additional information for safety and efficacy of pasireotide s.c.
Interventions
- DRUG Pasireotide sub-cutaneous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2011-08-16 |
| Est. Completion | 2017-01-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01582061
The ClinicalTrials.gov registry entry for NCT01582061 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pasireotide sub-cutaneous is the first listed.
NCT01582061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01582061 about?
NCT01582061 is a clinical study titled "An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.". This study provided access to pasireotide sc in patients with Cushing's disease.and provided additional information for safety and efficacy of pasireotide s.c.
What is the current status of trial NCT01582061?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2011-08-16. Estimated completion is 2017-01-26.
What interventions are being tested in trial NCT01582061?
The interventions under investigation include: Pasireotide sub-cutaneous (DRUG).
Who is sponsoring clinical trial NCT01582061?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.